1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | |
| brand | String | Caplyta |
| structure | File | |
| classes | List of String, delimiter: , | Atypical antipsychotic • 5HT2A/D2 antagonist with proposed differential pre/post-synaptic D2 activity |
| mechanism | String | |
| uses | String | Schizophrenia (FDA-approved Dec 2019). Bipolar depression as monotherapy or adjunct to lithium/valproate (FDA-approved Dec 2021). |
| starting_dose | String | 42 mg PO once daily with food (no titration) |
| preparations | String | 42 mg capsules |
| fda_max | String | 42 mg/d |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Antipsychotic effect over weeks |
| duration | String | Daily dosing |
| halflife | String | ~18 hours (terminal) |
| bioavailability | String | Limited but adequate; take with food |
| pregnancy | String | Limited data; National Pregnancy Registry for Atypical Antipsychotics |
| legal | String | Rx |
